期刊论文详细信息
Frontiers in Immunology
A Recombinant MVA-Based RSV Vaccine Induces T-Cell and Antibody Responses That Cooperate in the Protection Against RSV Infection
Markus Kalla1  Paul Chaplin1  Jana Haug1  Hubertus Hochrein1  Ariane Volkmann1  Yvonne Wollmann1  Markus Feigl1  Constanze Bernig1  Kathrin Endt1  Alexander Heiseke1  Mark Suter2 
[1] Bavarian Nordic GmbH, Martinsried, Germany;University of Zürich, Dekanat Vetsuisse-Fakultät Immunology, Zurich, Switzerland;
关键词: MVA;    vaccines;    RSV;    protection;    mode of action;   
DOI  :  10.3389/fimmu.2022.841471
来源: DOAJ
【 摘 要 】

Respiratory syncytial virus (RSV) causes a respiratory disease with a potentially fatal outcome especially in infants and elderly individuals. Several vaccines failed in pivotal clinical trials, and to date, no vaccine against RSV has been licensed. We have developed an RSV vaccine based on the recombinant Modified Vaccinia Virus Ankara-BN® (MVA-RSV), containing five RSV-specific antigens that induced antibody and T-cell responses, which is currently tested in clinical trials. Here, the immunological mechanisms of protection were evaluated to determine viral loads in lungs upon vaccination of mice with MVA-RSV followed by intranasal RSV challenge. Depletion of CD4 or CD8 T cells, serum transfer, and the use of genetically engineered mice lacking the ability to generate either RSV-specific antibodies (T11µMT), the IgA isotype (IgA knockout), or CD8 T cells (β2M knockout) revealed that complete protection from RSV challenge is dependent on CD4 and CD8 T cells as well as antibodies, including IgA. Thus, MVA-RSV vaccination optimally protects against RSV infection by employing multiple arms of the adaptive immune system.

【 授权许可】

Unknown   

  文献评价指标  
  下载次数:0次 浏览次数:0次